Radius Health (RDUS) Shares Down 0.5%

Radius Health Inc (NASDAQ:RDUS) fell 0.5% on Tuesday . The company traded as low as $16.45 and last traded at $16.56. 20,819 shares traded hands during mid-day trading, a decline of 97% from the average session volume of 734,247 shares. The stock had previously closed at $16.65.

A number of brokerages have recently weighed in on RDUS. Cowen restated a “hold” rating on shares of Radius Health in a report on Thursday, October 18th. Zacks Investment Research lowered shares of Radius Health from a “hold” rating to a “sell” rating in a research note on Tuesday, October 9th. BidaskClub upgraded shares of Radius Health from a “strong sell” rating to a “sell” rating in a research note on Tuesday, October 2nd. Jefferies Financial Group reiterated a “hold” rating and set a $25.00 price target on shares of Radius Health in a research note on Tuesday, August 7th. Finally, Bank of America cut their price target on shares of Radius Health from $51.00 to $47.00 and set a “buy” rating on the stock in a research note on Wednesday, July 25th. Three research analysts have rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $49.14.

The company has a current ratio of 5.39, a quick ratio of 5.26 and a debt-to-equity ratio of 1.26. The company has a market capitalization of $803.57 million, a P/E ratio of -2.87 and a beta of 0.95.



Radius Health (NASDAQ:RDUS) last announced its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.99) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.35) by $0.36. The firm had revenue of $22.63 million for the quarter, compared to analyst estimates of $20.84 million. Radius Health had a negative net margin of 444.70% and a negative return on equity of 110.71%. As a group, research analysts expect that Radius Health Inc will post -5.42 EPS for the current year.

In other Radius Health news, major shareholder Growth N. V. Biotech acquired 169,363 shares of the company’s stock in a transaction on Wednesday, August 15th. The shares were bought at an average cost of $20.83 per share, for a total transaction of $3,527,831.29. Following the completion of the purchase, the insider now owns 6,460,913 shares in the company, valued at approximately $134,580,817.79. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Growth N. V. Biotech acquired 60,000 shares of the company’s stock in a transaction on Wednesday, August 8th. The stock was acquired at an average price of $22.73 per share, for a total transaction of $1,363,800.00. Following the completion of the purchase, the insider now owns 6,360,913 shares of the company’s stock, valued at approximately $144,583,552.49. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 289,363 shares of company stock worth $6,070,631. 3.42% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. BB Biotech AG increased its stake in Radius Health by 5.9% in the second quarter. BB Biotech AG now owns 6,200,913 shares of the biopharmaceutical company’s stock valued at $182,741,000 after purchasing an additional 347,114 shares during the period. Voya Investment Management LLC increased its stake in Radius Health by 4.3% in the second quarter. Voya Investment Management LLC now owns 731,818 shares of the biopharmaceutical company’s stock valued at $21,567,000 after purchasing an additional 30,003 shares during the period. Northern Trust Corp increased its stake in Radius Health by 10.1% in the second quarter. Northern Trust Corp now owns 480,107 shares of the biopharmaceutical company’s stock valued at $14,149,000 after purchasing an additional 44,104 shares during the period. Bank of America Corp DE increased its stake in Radius Health by 22.3% in the second quarter. Bank of America Corp DE now owns 413,991 shares of the biopharmaceutical company’s stock valued at $12,201,000 after purchasing an additional 75,462 shares during the period. Finally, Artisan Partners Limited Partnership acquired a new position in Radius Health in the second quarter valued at $6,763,000.

About Radius Health (NASDAQ:RDUS)

Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide that is in Phase III clinical trial to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator that is in Phase I clinical trial to treat breast cancer.

See Also: Discount Rate

Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply